• 1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 2. An intermolecular C–H oxidizing strategy to access highly fused carbazole skeletons from simple naphthylamines?
  Christian K. Rank,Alexander W. Jones,Tatjana Wall,Patrick Di Martino-Fumo,Sarah Schr?ck,Markus Gerhards,Frederic W. Patureau Chem. Commun., 2019,55, 13749-13752
• 3. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 4. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (CAS No. 111635-08-6): A Comprehensive Overview

1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, commonly referred to by its CAS number 111635-08-6, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the tetrahydroisoquinoline class of alkaloids, which have garnered considerable attention due to their diverse biological activities and potential therapeutic applications. The hydrochloride salt form enhances its solubility and stability, making it a valuable intermediate in synthetic chemistry and a candidate for further pharmacological investigation.

The structure of 1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride consists of a bicyclic system featuring a benzene ring fused with a piperidine ring. The presence of a methyl group at the 1-position and the tetrahydroisoquinoline core contribute to its unique chemical properties and biological interactions. This molecular framework has been extensively studied for its role in modulating various neurological and cardiovascular pathways.

In recent years, research on tetrahydroisoquinoline derivatives has intensified due to their reported pharmacological effects. Studies have highlighted the potential of these compounds in treating neurological disorders such as Parkinson's disease and depression. The mechanism of action often involves interaction with neurotransmitter receptors, particularly dopamine and serotonin receptors, which are crucial for regulating mood and motor function.

One of the most compelling aspects of 1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is its role as a precursor in the synthesis of more complex bioactive molecules. Researchers have leveraged its structural motifs to develop novel drugs that target specific pathological pathways. For instance, derivatives of this compound have been explored for their anti-inflammatory and analgesic properties, demonstrating promise in preclinical models.

The synthesis of 1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride typically involves multi-step organic reactions starting from readily available aromatic precursors. The process often includes cyclization reactions followed by functional group modifications to introduce the necessary substituents. The hydrochloride salt is formed by treating the free base with hydrochloric acid, ensuring high purity and stability for further applications.

Advances in computational chemistry have also facilitated the study of this compound's interactions with biological targets. Molecular docking simulations have been employed to predict binding affinities and identify potential lead compounds for drug development. These computational approaches complement traditional experimental methods, providing a more efficient pipeline for discovering novel therapeutic agents.

The pharmacokinetic profile of 1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is another area of active investigation. Understanding how the body processes this compound is crucial for optimizing its therapeutic efficacy and minimizing potential side effects. Studies have examined its absorption, distribution, metabolism, and excretion (ADME) properties to guide dosing regimens and formulation strategies.

In conclusion, 1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (CAS No. 111635-08-6) represents a fascinating compound with significant potential in pharmaceutical research. Its unique structural features and reported biological activities make it a valuable candidate for further exploration. As research continues to uncover new applications and refine synthetic methodologies, this compound is poised to play an important role in the development of next-generation therapeutics.

• 4965-09-7(1-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)